Humanized anti-B7 antibodies (Pfizer)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHumanized anti-B7 antibodies (Pfizer)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionCluster of differentiation 80 inhibitors

TargetsCluster of differentiation 80

Therapy Area/IndicationsRejection of organ transplantationGraft vs Host Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsRejection of organ transplantationGraft vs Host Disease

ATC CodeN/A